QQQ   444.02 (-0.36%)
AAPL   175.10 (-2.54%)
MSFT   414.92 (-0.14%)
META   498.19 (-0.82%)
GOOGL   133.35 (-2.76%)
AMZN   177.58 (-0.36%)
TSLA   188.14 (-7.16%)
NVDA   852.37 (+3.60%)
NIO   5.35 (-7.44%)
AMD   205.36 (+1.34%)
BABA   72.00 (-3.51%)
T   16.80 (-1.06%)
F   12.74 (+2.33%)
MU   95.77 (+0.65%)
CGC   3.02 (-5.92%)
GE   161.04 (+1.51%)
DIS   113.69 (+1.55%)
AMC   4.32 (-0.92%)
PFE   25.89 (-2.63%)
PYPL   59.98 (-0.93%)
XOM   104.36 (-1.40%)
QQQ   444.02 (-0.36%)
AAPL   175.10 (-2.54%)
MSFT   414.92 (-0.14%)
META   498.19 (-0.82%)
GOOGL   133.35 (-2.76%)
AMZN   177.58 (-0.36%)
TSLA   188.14 (-7.16%)
NVDA   852.37 (+3.60%)
NIO   5.35 (-7.44%)
AMD   205.36 (+1.34%)
BABA   72.00 (-3.51%)
T   16.80 (-1.06%)
F   12.74 (+2.33%)
MU   95.77 (+0.65%)
CGC   3.02 (-5.92%)
GE   161.04 (+1.51%)
DIS   113.69 (+1.55%)
AMC   4.32 (-0.92%)
PFE   25.89 (-2.63%)
PYPL   59.98 (-0.93%)
XOM   104.36 (-1.40%)
QQQ   444.02 (-0.36%)
AAPL   175.10 (-2.54%)
MSFT   414.92 (-0.14%)
META   498.19 (-0.82%)
GOOGL   133.35 (-2.76%)
AMZN   177.58 (-0.36%)
TSLA   188.14 (-7.16%)
NVDA   852.37 (+3.60%)
NIO   5.35 (-7.44%)
AMD   205.36 (+1.34%)
BABA   72.00 (-3.51%)
T   16.80 (-1.06%)
F   12.74 (+2.33%)
MU   95.77 (+0.65%)
CGC   3.02 (-5.92%)
GE   161.04 (+1.51%)
DIS   113.69 (+1.55%)
AMC   4.32 (-0.92%)
PFE   25.89 (-2.63%)
PYPL   59.98 (-0.93%)
XOM   104.36 (-1.40%)
QQQ   444.02 (-0.36%)
AAPL   175.10 (-2.54%)
MSFT   414.92 (-0.14%)
META   498.19 (-0.82%)
GOOGL   133.35 (-2.76%)
AMZN   177.58 (-0.36%)
TSLA   188.14 (-7.16%)
NVDA   852.37 (+3.60%)
NIO   5.35 (-7.44%)
AMD   205.36 (+1.34%)
BABA   72.00 (-3.51%)
T   16.80 (-1.06%)
F   12.74 (+2.33%)
MU   95.77 (+0.65%)
CGC   3.02 (-5.92%)
GE   161.04 (+1.51%)
DIS   113.69 (+1.55%)
AMC   4.32 (-0.92%)
PFE   25.89 (-2.63%)
PYPL   59.98 (-0.93%)
XOM   104.36 (-1.40%)
NASDAQ:AMED

Amedisys (AMED) Stock Price, News & Analysis

$92.97
-0.37 (-0.40%)
(As of 03/4/2024 ET)
Today's Range
$92.64
$93.37
50-Day Range
$92.97
$95.27
52-Week Range
$69.36
$96.44
Volume
532,826 shs
Average Volume
297,351 shs
Market Capitalization
$3.04 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$100.43

Amedisys MarketRank™ Stock Analysis

Analyst Rating
Hold
2.00 Rating Score
Upside/​Downside
8.0% Upside
$100.43 Price Target
Short Interest
Bearish
9.42% of Float Sold Short
Dividend Strength
N/A
Sustainability
-0.61
Upright™ Environmental Score
News Sentiment
1.34mentions of Amedisys in the last 14 days
Based on 5 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
8.93%
From $4.48 to $4.88 Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

2.51 out of 5 stars

Medical Sector

539th out of 960 stocks

Home Health Care Services Industry

5th out of 7 stocks


AMED stock logo

About Amedisys Stock (NASDAQ:AMED)

Amedisys, Inc., together with its subsidiaries, provides healthcare services in the United States. It operates through four segments: Home Health, Hospice, Personal Care, and High Acuity Care. The Home Health segment offers a range of services in the homes of individuals for the recovery of patients from surgery, chronic disability, or terminal illness, as well as prevents avoidable hospital readmissions through its skilled nurses; nursing services, rehabilitation therapists specialized in physical, speech, and occupational therapy; and social workers and aides for assisting its patients. The Hospice segment offers services that is designed to provide comfort and support for those who are dealing with a terminal illness, including cancer, heart disease, pulmonary disease, or Alzheimer's. The Personal Care segment provides assistance for patients with the activities of daily living. The High Acuity Care offers essential elements of inpatient hospital, skilled nursing facility care, and palliative care to patients in their homes. Amedisys, Inc. was incorporated in 1982 and is headquartered in Baton Rouge, Louisiana.

AMED Stock Price History

AMED Stock News Headlines

StockNews.com Initiates Coverage on Amedisys (NASDAQ:AMED)
This is the #1 Stock to Buy for the AI Tidal Wave
Marc Chaikin warned people about NVDA before its 2023 bull run - now he’s naming his next pick or the AI tidal wave. Learn more here.
CAH Mar 2024 103.000 put
Q4 2023 Blue Owl Capital Corp Earnings Call
Critical asset just had biggest fall on record
What many consider America's critical financial asset suffers biggest fall on record. Expert says: "it's very bad for millions, protect yourself now."
Amedisys (AMED) Q4 Earnings Lag Estimates
Kain Capital-Backed PERA Holdings Hires CEO and CCO
AMED Mar 2024 95.000 put
AMED Mar 2024 70.000 put
AMED Feb 2024 90.000 call
Best Pregnancy Pillows of 2024
Scoop: Infusion Associates coming to market
See More Headlines
Receive AMED Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Amedisys and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
2/21/2024
Today
3/04/2024
Next Earnings (Estimated)
5/01/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Home health care services
Sub-Industry
Health Care Services
Current Symbol
NASDAQ:AMED
CUSIP
02343610
Employees
19,000
Year Founded
1982

Price Target and Rating

Average Stock Price Target
$100.43
High Stock Price Target
$115.00
Low Stock Price Target
$81.00
Potential Upside/Downside
+8.0%
Consensus Rating
Hold
Rating Score (0-4)
2.00
Research Coverage
8 Analysts

Profitability

Net Income
$-9,750,000.00
Pretax Margin
1.77%

Debt

Sales & Book Value

Annual Sales
$2.24 billion
Cash Flow
$6.09 per share
Book Value
$34.31 per share

Miscellaneous

Free Float
32,080,000
Market Cap
$3.04 billion
Optionable
Optionable
Beta
0.86

Social Links

5G Stocks: The Path Forward is Profitable Cover

Click the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

Key Executives















AMED Stock Analysis - Frequently Asked Questions

Should I buy or sell Amedisys stock right now?

8 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Amedisys in the last year. There are currently 8 hold ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" AMED shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in AMED, but not buy additional shares or sell existing shares.
View AMED analyst ratings
or view top-rated stocks.

What is Amedisys' stock price target for 2024?

8 brokerages have issued 1-year target prices for Amedisys' stock. Their AMED share price targets range from $81.00 to $115.00. On average, they anticipate the company's share price to reach $100.43 in the next year. This suggests a possible upside of 8.0% from the stock's current price.
View analysts price targets for AMED
or view top-rated stocks among Wall Street analysts.

How have AMED shares performed in 2024?

Amedisys' stock was trading at $95.06 at the beginning of 2024. Since then, AMED stock has decreased by 2.2% and is now trading at $92.97.
View the best growth stocks for 2024 here
.

When is Amedisys' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 1st 2024.
View our AMED earnings forecast
.

How were Amedisys' earnings last quarter?

Amedisys, Inc. (NASDAQ:AMED) announced its earnings results on Wednesday, February, 21st. The health services provider reported $0.94 EPS for the quarter, missing the consensus estimate of $1.04 by $0.10. The health services provider earned $570.79 million during the quarter, compared to the consensus estimate of $566.85 million. Amedisys had a negative net margin of 0.44% and a positive trailing twelve-month return on equity of 12.76%. The firm's revenue was up 1.6% compared to the same quarter last year. During the same quarter in the previous year, the company earned $1.16 earnings per share.

What ETFs hold Amedisys' stock?
What is Paul B. Kusserow's approval rating as Amedisys' CEO?

478 employees have rated Amedisys Chief Executive Officer Paul B. Kusserow on Glassdoor.com. Paul B. Kusserow has an approval rating of 79% among the company's employees. 60.0% of employees surveyed would recommend working at Amedisys to a friend.

What other stocks do shareholders of Amedisys own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Amedisys investors own include NVIDIA (NVDA), Alibaba Group (BABA), Johnson & Johnson (JNJ), Pfizer (PFE), Adobe (ADBE), Intel (INTC), QUALCOMM (QCOM), Broadcom (AVGO), Cisco Systems (CSCO) and Home Depot (HD).

Who are Amedisys' major shareholders?

Amedisys' stock is owned by a number of retail and institutional investors. Top institutional shareholders include Vanguard Group Inc. (9.86%), FIL Ltd (4.00%), Alpine Associates Management Inc. (3.90%), Westchester Capital Management LLC (2.70%), Mackenzie Financial Corp (2.69%) and Park West Asset Management LLC (2.49%). Insiders that own company stock include Bruce D Perkins, Christopher Gerard, David L Kemmerly, David L Kemmerly, Denise M Bohnert, Michael Paul North, Richard A Lechleiter and Scott G Ginn.
View institutional ownership trends
.

How do I buy shares of Amedisys?

Shares of AMED stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:AMED) was last updated on 3/4/2024 by MarketBeat.com Staff